Memorial Sloan Kettering Cancer Center Update on the Treatment of Pituitary Tumors 2024

Friday, April 5, 2024, 9:00 AM – 4:00 PM, Online, New York, NY

This didactic and case-based program will update attendees on the latest developments in ongoing basic and translational science and the clinical management of patients with pituitary conditions. This course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies. Our goal is to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for the dissemination of knowledge across the variety of practitioners caring for patients with pituitary diseases and for the patients themselves.

Afternoon Breakout Tracks

The afternoon will comprise of two separate interactive tracks – a clinical track for providers and a separate track geared towards patients and caregivers.

Provider/Clinical Track: Request for Case Submissions

During the provider/clinical track, there will be an interactive tumor board providing attendees and faculty an opportunity to review cases. We invite the submission of cases for discussion during this session. Submission should be made at registration. In order to prepare your submission, we ask that you provide a BRIEF summary of your case and include key lab results. Please ensure that all identifiable PHI has been removed. Cases should have an educational purpose. The course faculty will not be able to provide a detailed/complex consult review during the course and will try to get through as many cases as possible.

Patient/Caregiver Track

Patients with pituitary disease and their caregivers are invited to attend this educational activity on a complimentary basis and participate in this interactive track. Pituitary patients can review treatment options, learn about ongoing clinical trials, and discuss their comprehensive care with providers and other patients. The educational objective of this patient session is to provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients. Please note AMA PRA Category 1 Credits™ will not be offered for the patient breakout session.

Overall this course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies in order to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases.

This educational activity is presented by the Memorial Sloan Kettering Multidisciplinary Pituitary & Skull Base Tumor Center and endorsed by the Cushing’s Support & Research Foundation (CSRF) and Acromegaly Community.

Who Should Attend

This course is intended for endocrinologists, neurosurgeons, otolaryngologists, radiation oncologists, neurologists, ophthalmologists, neuro-oncologists, family medicine and internal medicine physicians, physicians in training, and other allied health professionals who treat and manage patients with pituitary diseases. We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions.

Please note this program will be held virtually via Zoom. Detailed access instructions will be emailed to attendees prior to the start of the event.

Online Syllabus

Attendees will receive access to a syllabus after the program concludes, which will include select PDFs of the faculty presentations (slides) and video clips. Attendees must check in during the live program in order to receive access to the syllabus.

1. Review available and emerging medical therapies for Cushing’s and acromegaly
2. Explain decision making involved in surgical interventions for pituitary tumors
3. Discuss the use of patient reported outcomes for pituitary patients
4. Present recent data on mechanisms for the development of treatment resistant and malignant pituitary tumors
5. Debate treatment decisions supporting the use and timing of new therapies for treatment resistant and malignant pituitary tumors